Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @DicernaPharma
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DicernaPharma
-
Dicerna Pharmaceuticals proslijedio/la je Tweet
At the 2019 Global Genes Patient Advocacy Summit, our RARE Revolution team had the privilege of hosting a roundtable in partnership with Dicerna Pharmaceuticals and the Oxalosis and Hyperoxaluria Foundation. Open: http://bit.ly/2R4cIQ2
#RareDisease#PrimaryHyperoxaluriapic.twitter.com/r7vtqV6d7u
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dicerna Pharmaceuticals proslijedio/la je Tweet
Don't miss this Interview with the 2019 OTS Lifetime Achievement Award Winner Muthiah (Mano) Manoharan!
$ALNY$ARWR$DRNA$ABUS$SLN$AMGN@OliXPharmaceut1#siRNA#RNAi@RNAi_papers@JMaraganore@Alnylam@ArrowheadPharma@SilenceTheraPlc@DicernaPharma https://www.oligotherapeutics.org/interview-with-mano-manoharan/ …pic.twitter.com/0eS9Ww4w0I
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dicerna and
@Roche are harnessing Dicerna's GalXC™ technology to develop DCR-HBVS (RG6346) and novel therapies for chronic#HBV. Learn more here: http://dicerna.com/pipeline/ pic.twitter.com/KQK1Eh0wq1
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At Dicerna, we foster a culture of innovation through collaboration. View our list of current
#career opportunities on our careers page: http://dicerna.com/careers https://dicerna.com/careers/Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dicerna is developing nedosiran (DCR-PHXC) for the treatment of
#primaryhyperoxaluria, for which there are currently no approved treatments. Learn more here: http://dicerna.com/pipeline/primary-hyperoxaluria/ …pic.twitter.com/zgAcinvAFP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Looking to be a part of a dynamic team in
#biotech? Visit our careers page to view current opportunities: https://dicerna.com/careers/#DiscoverDicernapic.twitter.com/LaZivTasXs
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dicerna Pharmaceuticals proslijedio/la je Tweet
Join us for the Los Angeles Alpha-1 Education Day on February 29, in conjunction with Rare Disease Day! We invite all Alphas, family members, caregivers, friends, healthcare providers, to attend this day-long event on the latest Alpha-1 topics. Visit http://ow.ly/L2iz50y1rjR pic.twitter.com/oPYiSexuj6
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
At Dicerna,
#WeInterfere to fight disease. To learn more about us, visit our website: https://dicerna.com/ pic.twitter.com/I6a3HSyYv3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In the January issue of
@PharmaVOICE, Doug Fambrough sheds light on why#RNAi is an attractive area for research and shares how Dicerna is working toward its goal of providing innovative treatment options to rare and genetic disease communities. Read here:https://www.pharmavoice.com/article/2020-01-rnai …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dicerna announced the successful closing of the discovery and development agreement between Dicerna and Novo Nordisk for treatments for liver-related cardio-metabolic diseases. Read more here:https://bit.ly/39tV4MO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you're looking to work in
#biotech, then Dicerna may be a good fit for you. Visit our website for more information on current employment opportunities: http://dicerna.com/careers pic.twitter.com/ttRoWO7LSZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dicerna announced the successful closing of the research collaboration and licensing agreement between Dicerna and Roche for treatments for chronic hepatitis B virus infection. Read more here: https://bit.ly/34BKakn pic.twitter.com/nbSqTVC5yE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Primary hyperoxaluria occurs in an estimated 1 in 120,000 live births around the world. It is estimated that more than 5,000 people in the United States and European Union are living with
#PH. For more about Dicerna's PHYOX trials, visit:http://phyoxtrials.comHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Approximately 10% of infants with A1AT deficiency develop liver disease, and about 15% of adults with A1AT deficiency develop cirrhosis. Learn more about our A1AT program here:http://dicerna.com/pipeline
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dicerna receives orphan drug designation from the European Commission for DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency. Read more here https://bit.ly/35vMbQw
#DicernaPharma#DRNAHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dicerna and Alexion announced that Alexion exercised its option for exclusive rights to two additional targets within the complement pathway for the discovery and development of GalXC™ RNAi molecules. Learn more here https://bit.ly/34s4CUR
#DRNA#ALXNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dicerna Pharmaceuticals proslijedio/la je Tweet
#RareDiseaseDay in Dubai! For the third time@highhopesdubai and @rarediseasedaydubai are organising a walk and kite flying for Rare Disease Day 2020! Head to http://ow.ly/91R850wWpvg to find out what events are taking place in your country for Rare Disease Day 2020!pic.twitter.com/v6ITFvvG7t
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dicerna Pharmaceuticals proslijedio/la je Tweet
Today we announced an extension of our collaboration with
@DicernaPharma. https://bit.ly/2sv3lPG pic.twitter.com/oRs75QQPiZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
To learn more about Dicerna's DCR-HBVS, a GalXC RNAi platform-based product candidate for the treatment of chronic
#HBV, please visit:http://dicerna.com/pipelineHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you or someone you know has
#primaryhyperoxaluria, visit our website to learn more about Dicerna's PHYOX clinical trials: http://phyoxtrials.com pic.twitter.com/tfPtEMBb1X
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.